创新药牛股大消息

Core Insights - Micron Biotech announced the final top-line analysis data from the Phase III clinical trial of its self-developed drug, Sidabone, showing significant improvement in event-free survival (EFS) compared to the control group, achieving the primary endpoint of the study [1][6] - The stock price of Micron Biotech has surged by 103% since May 28, reaching a closing price of 31.3 yuan per share on July 9, with a market capitalization of 12.8 billion yuan [1] Group 1 - Sidabone is a novel mechanism drug and the first subtype-selective histone deacetylase (HDAC) inhibitor globally, representing a significant achievement in China's innovative drug development [3] - The drug has received conditional approval from the National Medical Products Administration for use in previously untreated DLBCL patients expressing MYC and BCL2, based on interim analysis data from the DEB study [4] - By the end of 2024, Sidabone will be included in the national medical insurance directory as the only oral innovative drug for first-line DLBCL treatment [5] Group 2 - The combination of Sidabone and R-CHOP (CR-CHOP) has shown a statistically significant improvement in complete response (CR) rates compared to R-CHOP alone in the Phase III clinical trial for DLBCL [6] - The company is preparing to submit for routine approval for this indication, with comprehensive analysis results expected to be presented at upcoming academic conferences or journals [6]